Curative Biotechnology (OTCMKTS:CUBT) and Inovio Pharmaceuticals (NASDAQ:INO) Head to Head Comparison

Curative Biotechnology (OTCMKTS:CUBT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Curative Biotechnology and Inovio Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curative Biotechnology	0	0	0	0	0.00
Inovio Pharmaceuticals	0	2	3	0	2.60

Inovio Pharmaceuticals has a consensus target price of $8.80, suggesting a potential upside of 363.16%. Given Inovio Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Curative Biotechnology.

Institutional and Insider Ownership

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 2.3% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Curative Biotechnology and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curative Biotechnology	N/A	N/A	N/A
Inovio Pharmaceuticals	N/A	-163.32%	-96.41%

Risk & Volatility

Curative Biotechnology has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Valuation & Earnings

This table compares Curative Biotechnology and Inovio Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
Inovio Pharmaceuticals	$220,000.00	316.70	-$107.25 million	($2.61)	-0.73

Curative Biotechnology has higher earnings, but lower revenue than Inovio Pharmaceuticals.

Summary

Inovio Pharmaceuticals beats Curative Biotechnology on 7 of the 9 factors compared between the two stocks.

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.